1-11 of 11
Mark Geyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl

Free
Hoda Pourhassan, Jianying Zhang, Wendy Stock, Mark Geyer, Anjali Advani, Jae Park, Emily Curran, Katrin Tiemann, Vaibhav Agrawal, Paul Koller, Jose Tinajero, Tibor Kovacsovics, Anthony Selwyn Stein, Guido Marcucci, Melisa Stricherz, Stefan Faderl, Vinod Pullarkat, Ibrahim Aldoss
Journal: Blood
Blood (2025) 146 (Supplement 1): 8233.
https://doi.org/10.1182/blood-2025-8233
Published: 2025
Journal Articles

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Free
Kuo-Kai Chin, Brian Ball, Yasmin Abaza, Jessica Altman, Rahul Thakur, Moiez Ali, Andriy Derkach, Mark Geyer, Aaron Goldberg, Tamanna Haque, Meghan Thompson, Jae Park, Martin Tallman, Sheng Cai, Eunice Wang, Ibrahim Aldoss, Eytan Stein
Journal: Blood
Blood (2025) 146 (Supplement 1): 39.
https://doi.org/10.1182/blood-2025-39
Published: 2025
Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Free
William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz
Journal: Blood
Blood (2025) 146 (Supplement 1): 2996.
https://doi.org/10.1182/blood-2025-2996
Published: 2025
Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Free
Keshu Zhou, Tingyu Wang, Wei Yang, Jian-Qing Mi, Sujun Gao, Huayuan Zhu, Xutao Guo, Kaiyang Ding, Ying Xiang, Huili Cai, Guohui Cui, Yun Zhuang, Hongmei Jing, Liping Su, Rui Huang, Lihua Qiu, Mark Geyer, Wuhan Hui, Geoffrey Chong, Meifang Zheng, Yi Wang, Ying Li, Ke Fang, Chan Cheah, Jianyong Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 3889.
https://doi.org/10.1182/blood-2025-3889
Published: 2025
Journal Articles

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Free
Meghan Thompson, Anthony Mato, Andrew Zelenetz, Jae Park, Mark Geyer, Andriy Derkach, David Nemirovsky, Deborah Stephens, Catherine Coombs, Prioty Islam, Christopher Jensen, Lorenzo Falchi, Lia Palomba, Anita Kumar, Gilles Salles, Eytan Stein, Jennifer Lue, Lauren Nogan, Bejal Kikani, Ryan Sutterby, Thu Quynh Nguyen, Alexandra Allen, Sumathy Sudhir, Gail Panton, Victoria Duffy, Dianna Tyznar, Jamila Brutus, Tenzin Nyima, Anmol Shah, Dhara Soni, Michael Silvestrone, Monica Shah, Miranda Harris, Megha Karnam, Claire Hutzler, Kevin David, Aaron Goldberg, Stephen Fleming, Giovanni Diaz, Habib Hamidi, Bita Fakhri, Lindsey Roeker
Journal: Blood
Blood (2025) 146 (Supplement 1): 3902.
https://doi.org/10.1182/blood-2025-3902
Published: 2025
Journal Articles

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Free
Benjamin Frost, Yannis Valtis, Yael Flamand, Emilie Baxter, David Nemirovsky, Andriy Derkach, Kuo-Kai Chin, Meira Yisraeli Salman, Leora Boussi, Natalia Tijaro Ovalle, Eytan Stein, Mark Geyer, Shai Shimony, Jacqueline Garcia, Martha Wadleigh, Eric Winer, Virginia Volpe, Maximilian Stahl, Richard Stone, Daniel Deangelo, Jae Park, Marlise Luskin, Evan Chen
Journal: Blood
Blood (2025) 146 (Supplement 1): 3329.
https://doi.org/10.1182/blood-2025-3329
Published: 2025
Journal Articles

Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL)

Free
Michaela Liedtke, Nikesh Shah, Jessica Leonard, Anthony Proli, Yazan Barqawi, Hui-Han Chen, Alan Yong, Vikram Shetty, Elias Jabbour, Mark Geyer
Journal: Blood
Blood (2025) 146 (Supplement 1): 1555.
https://doi.org/10.1182/blood-2025-1555
Published: 2025
Journal Articles

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Free
Meghan Thompson, Anthony Mato, Lia Palomba, Lori Leslie, Andriy Derkach, David Nemirovsky, Prioty Islam, Mark Geyer, Philip Caron, Aaron Goldberg, Anita Kumar, Alison Moskowitz, Jennifer Lue, Colette Owens, Gilles Salles, Eytan Stein, Raphael Steiner, Pallawi Torka, Lori Dahncke, Emily Ordona, Mashiyate Meem, Claire Hutzler, Miranda Harris, Monica Shah, Megha Karnam, Lauren Nogan, Caitlin Maloney, Anmol Shah, Tenzin Nyima, Colleen Dorsey, Kate Doyle, Jennifer Howgate-Klingaman, Jamila Brutus, Dianna Tyznar, Anna Lincke, Rick Wray, Tatyana Feldman, Andrew Zelenetz, Lindsey Roeker
Journal: Blood
Blood (2025) 146 (Supplement 1): 5676.
https://doi.org/10.1182/blood-2025-5676
Published: 2025
Journal Articles

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Free
Yannis Valtis, Benjamin Frost, David Nemirovsky, Andriy Derkach, Kuo-Kai Chin, Meira Yisraeli Salman, Leora Boussi, Natalia Tijaro Ovalle, Eytan Stein, Emilie Baxter, Mark Geyer, Marlise Luskin, Daniel Deangelo, Jae Park, Evan Chen
Journal: Blood
Blood (2025) 146 (Supplement 1): 1078.
https://doi.org/10.1182/blood-2025-1078
Published: 2025
Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Free
Lori Muffly, Edward Abadir, Mark Geyer, Ryan Cassaday, Gregory Roloff, R. Alejandro Sica, Wendy Stock, Eileen McNulty, Maria Del Rosario, Xiao Shi, Yanbo Liu, Yong Yu, Yali Zhou, Ming Gao, Wengang Ge, Lu Han, Yajin Ni, Jiangtao Ren, Jan Davidson-Moncada, Nitin Jain
Journal: Blood
Blood (2025) 146 (Supplement 1): 5954.
https://doi.org/10.1182/blood-2025-5954
Published: 2025
Journal Articles

Reduced Toxicity Conditioning (RTC) Compared to Myeloablative Conditioning (MAC) Prior to Unrelated Cord Blood Transplantation (UCBT) in Pediatric Recipients Was Associated with Similar but Also Delayed Time to Immune Reconstitution and a Concomitant Significant Decrease in Grade II-IV Agvhd.

Free
Jason Freedman, M.D., Diane George, MD, Judith Jacobson, DrPH, MBA, Mark Geyer, AB, Carmella van de Ven, MA, Nathifa Fearon, RN, MSN, Claire Fanelli, RN, BSN, Bradford Tallamy, BA, Prakash Satwani, MD, Monica Bhatia, MD, James H. Garvin, Jr., MD, M. Brigid Bradley, MD, Tracey Schonfeld, RN, BSN, Lauren Harrison, RN, Erin Morris, RN, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2009) 114 (22): 2304.
https://doi.org/10.1182/blood.V114.22.2304.2304
Published: 2009